Cafelkibart

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameCafelkibart
Drug Alias NameLM-108
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionC-C chemokine receptor type 8 inhibitors
TargetsC-C chemokine receptor type 8
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesLaNova Medicines Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSino Biopharmaceutical LtdShanghai Pulmonary HospitalFudan University +[8] 
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursCarcinoma, Non-Small-Cell Lung +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A